TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Astellas to Buy OSI Pharmaceuticals for $4 Billion Astellas Pharma said Monday it will buy OSI Pharmaceuticals for $4 billion in an all-cash deal, the latest Japanese drug maker to pay a hefty premium for products to boost flagging profits. online.wsj.com |
Beyond the Hype: Intuitive Surgical's Hidden Growth Potential Ephemeral Euphoria submits: Back in 2007, when I made my first investment in Intuitive Surgical (ISRG), the maker of the da Vinci surgical robotic system, it was a nondescript, up-and-coming SMidcap followed more by swing traders than sell-side analysts, institutional investors, and the traditional investing masses. click to enlargeComplete Story » seekingalpha.com |
Household-Cleaner Injuries Remain High The rate of injuries among young children involving household cleaners dropped significantly, but the number of injuries is still high, according to a study. online.wsj.com |
European Regulators Remove GSK's Avandia From Market: Biotech's Latest Mishaps The Burrill Report submits: The European Medicines Agency is removing GlaxoSmithKline’s (GSK) diabetes drug Avandia from the market because the drug may increase a patient’s risk of heart failure. The U.S. Food and Drug Administration, in a coordinated announcement with the European regulator, agreed that the drug carries risks, but has decided to allow Avandia to remain on the market as a drug of last resort for patients that they have notified of the risks of heart failure associated with the drug. Avandia, once the best selling diabetes drug and the second best-seller in GSK’s product line, has seen sales of the drug drop dramatically since the controversy over its safety erupted. In 2009 sales reached nearly $1.2 billion, down from $3.2 billion in 2006. Sanofi-Aventis (SNY) said that its experimental treatment for limb ischemia failed in a late-stage clinical trail. The primary endpoint was to demonstrate the superiority of drug known as NV1FGF compared to a placebo in the prevention of major amputation or death from any cause over 12 months, whichever came first, in critical limb ischemia patients who were not eligible for revascularization. The company said it is evaluating its options on the development of the drug. Complete Story » seekingalpha.com |
Knee-Device Maker Slams FDA The maker of a knee-repair device said the government's recent move to bar its product was "totally unbelievable" and accused Food and Drug Administration officials of playing politics. online.wsj.com |